RISK EVALUATION AND MITIGATION STRATEGY (REMS)

I. GOAL

The goal of the XIAFLEX REMS is to mitigate the risks of corporal rupture (penile fracture) and other serious penile injuries associated with the use of XIAFLEX for Peyronie’s disease by:

- Training healthcare providers in how to properly administer XIAFLEX.
- Informing healthcare providers about the risks of corporal rupture (penile fracture) and other serious injuries to the penis.
- Informing healthcare providers about the need to counsel patients to communicate that risks of corporal rupture and other serious penile injuries are associated with the use of XIAFLEX in treating Peyronie’s disease and that patient adherence to post-injection instructions is important for the drug’s safety and effectiveness.
- Ensuring that XIAFLEX is dispensed only in certified pharmacies or healthcare settings for the treatment of Peyronie’s disease.
- Informing patients about the risks of corporal rupture and other serious penile injuries associated with the use of XIAFLEX in treating Peyronie’s disease and that adherence to post-injection instructions is important for the drug’s safety and effectiveness.

---

1 The REMS for Xiaflex was originally approved on February 2, 2010 with the Dupuytren’s contracture indication and released for that indication in November 2016.
II. REMS ELEMENTS

A. Elements to Assure Safe Use

1. Healthcare providers who prescribe XIAFLEX for Peyronie’s disease are specially certified.
   a. Endo Pharmaceuticals will ensure that healthcare providers who prescribe XIAFLEX for the treatment of Peyronie’s disease are specially certified.
   b. To become specially certified to prescribe XIAFLEX for the treatment of Peyronie’s disease, healthcare providers must:
      i. Read the Prescribing Information for XIAFLEX.
      ii. Complete the XIAFLEX REMS Healthcare Provider Training Program for Peyronie’s disease by:
          a. viewing the entire REMS Training Video for Administering XIAFLEX for Peyronie’s disease or
          b. reading the entire REMS Training Guide for Administering XIAFLEX for Peyronie’s disease
      iii. Agree to review with and provide a copy of the Patient Counseling Tool, “What You Need to Know about XIAFLEX Treatment for Peyronie’s disease: A Patient Guide,” to each patient to inform patients about the risks associated with the use of XIAFLEX and the need to follow important post-injection instructions.
      iv. Acknowledge that my practice setting must be a certified healthcare setting, or that I will use a certified pharmacy, enrolled in the XIAFLEX REMS Program.
      v. Complete and sign the Healthcare Provider Enrollment Form for Peyronie’s disease and submit it to the XIAFLEX REMS Program.
   c. Endo Pharmaceuticals will:
      i. Ensure that healthcare providers complete the Healthcare Provider Training Program for Peyronie’s disease and Healthcare Provider Enrollment Form for Peyronie’s disease before activating healthcare providers’ certification in the XIAFLEX REMS Program.
      ii. Ensure that healthcare providers are notified when they have been successfully certified by the XIAFLEX REMS Program for Peyronie’s disease.

2 For the purposes of this REMS, the terms “prescribe” and “prescription” include medication orders in outpatient settings or hospital settings.
iii. Maintain a validated secure database of healthcare providers who prescribe XIAFLEX for the treatment of Peyronie’s disease and their specialties in the XIAFLEX REMS Program. Endo Pharmaceuticals will ensure that the prescribers’ certification requirements are met and may de-certify non-compliant prescribers until the requirements are met.

iv. Ensure that the XIAFLEX REMS Healthcare Provider Training Program for Peyronie’s disease, Healthcare Provider Enrollment Form for Peyronie’s disease, and Patient Counseling Tool for Peyronie’s disease are available on the XIAFLEX REMS program website at www.XIAFLEXREMS.com and from the XIAFLEX REMS Program call center (1-877-313-1235).

These materials will be available within 60 calendar days of the most recent REMS modification approval through the following distribution methods:

- Accessed through the www.XIAFLEXREMS.com website
- Hard copy is available, upon request, through the XIAFLEX REMS Program call center (1-877-313-1235).

The following materials are part of the REMS and are appended:

- REMS Training Guide for Administering XIAFLEX for Peyronie’s disease
- REMS Training Video for Administering XIAFLEX for Peyronie’s disease (accessed at www.XIAFLEXREMS.com)
- Healthcare Provider Enrollment Form for Peyronie’s disease
- Patient Counseling Tool, *What You Need to Know About XIAFLEX Treatment for Peyronie’s disease: A Patient Guide*
- XIAFLEX REMS Program website (www.XIAFLEXREMS.com), main landing page of the REMS website and Program Certification Lookup for a certified healthcare provider and healthcare setting

2. **Pharmacies and healthcare settings that dispense**$^3$ XIAFLEX for Peyronie’s disease are specially certified.

   a. Endo Pharmaceuticals will:

   i. Ensure that XIAFLEX is only distributed to and dispensed for the treatment of Peyronie’s disease from pharmacies or healthcare settings (eg, hospitals, and outpatient clinics, and healthcare providers’ offices) that are specially certified.

   ii. Ensure that pharmacies or healthcare settings are recertified in the XIAFLEX REMS Program every 2 years.

---

$^3$ For the purposes of this REMS, “dispense” in an outpatient setting includes dispensing for administration in a provider’s office.
iii. To become certified to dispense XIAFLEX for the treatment of Peyronie’s disease, the pharmacy or healthcare setting must designate an Authorized Representative to coordinate the pharmacy or healthcare setting’s activities and assure compliance with the XIAFLEX REMS Program. The Authorized Representative must agree to the following:

a. Complete and sign the *Pharmacy/Healthcare Setting Enrollment Form for Peyronie’s disease* and submit it to the XIAFLEX REMS Program.

b. Put processes and procedures in place to verify, prior to dispensing XIAFLEX, that the healthcare provider prescribing XIAFLEX for Peyronie’s disease is certified in the XIAFLEX REMS Program.

c. Maintain a record of current certified prescribers.

d. Agree not to loan, sell or transfer XIAFLEX to another pharmacy, healthcare setting, prescriber, institution, or distributor.

e. To be audited to ensure compliance with the XIAFLEX REMS Program.

The following materials are part of the REMS and are appended:

- *XIAFLEX REMS Pharmacy/Healthcare Setting Enrollment Form for Peyronie’s disease*

**B. Implementation System**

An implementation system will be established for the XIAFLEX REMS Program to monitor and evaluate whether the elements to assure safe use are meeting the program’s goals.

1. Endo Pharmaceuticals will ensure that pharmacies or healthcare settings that dispense XIAFLEX for Peyronie’s disease are specially certified.

2. Endo Pharmaceuticals will maintain, monitor, and evaluate the implementation of the XIAFLEX REMS Program for Peyronie’s disease.

   a. Endo Pharmaceuticals will maintain a validated secure database of all certified pharmacies or healthcare settings.

   b. Endo Pharmaceuticals will send confirmation of certification to each certified pharmacy or healthcare setting.

   c. The database of certified healthcare providers who are certified to prescribe Xiaflex for the treatment of Peyronie’s disease will be accessible by the Authorized Representative at a pharmacy or certified healthcare setting and by contract distributors.

   d. Contract distributors will verify pharmacy or healthcare setting certification prior to distributing XIAFLEX.

   e. Endo Pharmaceuticals will maintain a XIAFLEX REMS Program call center (1-877-313-1235) to respond to questions from healthcare providers, pharmacies, and healthcare settings.
f. Endo Pharmaceuticals will ensure that within 60 calendar days of the approval of the most recent REMS modification all materials listed in or appended to the XIAFLEX REMS Program will be available through the XIAFLEX REMS Program website at www.XIAFLEXREMS.com and through the XIAFLEX REMS Program call center (1-877-313-1235).

g. Endo Pharmaceuticals will audit 10% of the certified pharmacies or healthcare settings annually to ensure that all processes and procedures are in place and functioning to support the requirements of the XIAFLEX REMS Program. Endo Pharmaceuticals will correct noncompliance with XIAFLEX REMS Program requirements.

h. Endo Pharmaceuticals will take reasonable steps to improve implementation of these elements and to maintain compliance with the XIAFLEX REMS Program requirements, as applicable.

3. Endo Pharmaceuticals will ensure that contract distributors maintain distribution records of all shipments of XIAFLEX.

4. Endo Pharmaceuticals will take reasonable steps to improve implementation of these elements and to maintain compliance with the XIAFLEX REMS Program requirements, as applicable.

C. **Timetable for Submission of Assessments**

Endo Pharmaceuticals will submit REMS Assessments to FDA at 6 months and 12 months from the date of the initial approval of the REMS for Peyronie’s disease (12/06/2013) and annually thereafter. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 calendar days before the submission date for that assessment. Endo Pharmaceuticals will submit each assessment so that it will be received by the FDA on or before the due date.
This guide discusses:

- The XIAFLEX® REMS and the risks of penile fracture or other serious injury to the penis
- The steps necessary to prepare and administer XIAFLEX®
- The in-office penile modeling procedure that is part of each XIAFLEX® treatment cycle
- The daily, at-home penile modeling activities that are performed by the patient for approximately 6 weeks after each treatment cycle
- Counseling your patient with the XIAFLEX® Patient Counseling Tool
Background

What is the XIAFLEX® REMS (Risk Evaluation and Mitigation Strategy)?
A REMS is a strategy to manage known or potential risks associated with a drug, and is required by the FDA to ensure that the benefits of the drug outweigh its risks. XIAFLEX® is only available under a restricted distribution program called the XIAFLEX® REMS because of the risks of penile fracture and other serious penile injury associated with using XIAFLEX® in treating Peyronie’s disease.

This training guide is part of the XIAFLEX® REMS program. This guide discusses:
- The steps necessary to prepare and administer XIAFLEX®
- The in-office penile modeling procedure that is part of each XIAFLEX® treatment cycle
- The daily, at-home penile modeling activities that are performed for 6 weeks after each treatment cycle
- Counseling your patient with the XIAFLEX® Patient Counseling Tool

Peyronie’s Disease

Peyronie’s disease is a localized connective tissue disorder characterized by changes in collagen composition in the tunica albuginea.¹ These changes cause an abnormal scar formation known as Peyronie’s plaque, which is typically a palpable bump under the skin.²⁻⁴ The Peyronie’s plaque is composed predominantly of collagen, and replaces the normally elastic fibers of the tunica albuginea. Microvascular trauma resulting from excessive bending or injury to the penis (possibly during sexual activity) is thought to be an important trigger for the inflammatory response and plaque development characteristic of Peyronie’s disease. Genetic predisposition and autoimmunity may also play a role in its development.

One of the hallmarks of Peyronie’s disease is penile curvature deformity. Peyronie’s disease may also cause other types of deformities, including narrowing, indentation, and shortening of the penis.

Indication

XIAFLEX® is indicated for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. XIAFLEX® is also indicated for the treatment of adult patients with Dupuytren’s contracture with a palpable cord.
XIAFLEX® contains 2 different types of purified collagenase clostridium histolyticum (AUX-I and AUX-II), in a defined mass ratio. Injection of XIAFLEX® into a Peyronie’s plaque, which is composed mostly of collagen, may result in enzymatic disruption of the collagen found in Peyronie’s plaque. Following this disruption of the collagen-containing plaque, penile curvature deformity may improve while Patient-Reported Bother may be reduced.

XIAFLEX® should be administered by a healthcare provider experienced in the treatment of male urological diseases, who has completed required training for use of XIAFLEX® in the treatment of Peyronie’s disease.

**XIAFLEX® Treatment Overview and Risk of Penile Injuries**

- **XIAFLEX®, supplied as a lyophilized powder, must be reconstituted with the provided diluent prior to use.**
- The dose of XIAFLEX® is 0.58 mg per injection administered into a Peyronie’s plaque. If more than one plaque is present, inject into the plaque causing the curvature deformity.
- Injection of XIAFLEX® into collagen-containing structures such as the corpora cavernosa of the penis may result in damage to those structures and possible injury such as corporal rupture (penile fracture). Therefore, XIAFLEX® should be injected only into the Peyronie’s plaque and care should be taken to avoid injecting into the urethra, nerves, blood vessels, corpora cavernosa or other collagen-containing structures of the penis.
- Healthcare providers must counsel patients on the risks of penile fractures or other serious injuries of the penis that can occur with XIAFLEX® treatment, such as penile hematoma, ecchymoses, swelling, and pain.
- An entire treatment course of XIAFLEX® consists of up to four treatment cycles and takes approximately 24 weeks to complete (see diagram below).

  - Each treatment cycle consists of four steps:
    1. First XIAFLEX® injection procedure
    2. Second XIAFLEX® injection procedure
      - The second XIAFLEX® injection procedure occurs one to three days after the first injection procedure.
    3. One in-office penile modeling procedure
      - The in-office penile modeling procedure is performed one to three days after the second injection procedure of each treatment cycle.
    4. Daily patient penile modeling at home
      - Six weeks of daily, at-home penile modeling activities after the in-office penile modeling procedure (Patients must be counseled on how to perform the at-home modeling activities as appropriate.)

- If the curvature deformity is less than 15 degrees after the first, second or third treatment cycle, or if the healthcare provider determines that further treatment is not clinically indicated, then the subsequent treatment cycles should not be administered.
- The safety of more than one treatment course of XIAFLEX® (comprising 4 treatment cycles) is not known.
XIAFLEX® Treatment Course

Each treatment cycle consists of 2 XIAFLEX® injection procedures and penile modeling. Each cycle takes approximately 6 weeks to complete.

<table>
<thead>
<tr>
<th>CYCLES</th>
<th>INJECTION PROCEDE</th>
<th>INJECTION PROCEDURE</th>
<th>HCP MODELING</th>
<th>Patient at-home DAILY MODELING</th>
<th>Approximately 6 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1st</td>
<td>2nd</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1-3 days</td>
<td>1-3 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1st</td>
<td>2nd</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1-3 days</td>
<td>1-3 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>1st</td>
<td>2nd</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1-3 days</td>
<td>1-3 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>1st</td>
<td>2nd</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1-3 days</td>
<td>1-3 days</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

An entire treatment course of XIAFLEX® consists of up to 4 cycles and takes approximately 24 weeks to complete.

Preparing for Administration

This section summarizes the procedure for reconstituting the lyophilized powder of XIAFLEX®.

XIAFLEX® is supplied in single-use glass vials containing 0.9 mg of collagenase clostridium histolyticum as a sterile, lyophilized powder for reconstitution. Sterile diluent for reconstitution is supplied in the package in a single-use glass vial containing 3 mL of 0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride. XIAFLEX® must be reconstituted with the provided diluent prior to use.

Prior to reconstitution, the vials of lyophilized powder of XIAFLEX® and sterile diluent should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

Before Use

1. Remove the vial containing the lyophilized powder of XIAFLEX® and the vial containing the diluent for reconstitution from the refrigerator and check the labels on both the diluent vial and the lyophilized powder vial to make sure they have not expired. Allow the 2 vials to stand at room temperature for at least 15 minutes but no longer than 60 minutes.
2. Visually inspect the vial containing XIAFLEX®. The cake of lyophilized powder should be intact and white in color. If the cake has been eroded, it should not be used and should be reported to the XIAFLEX® Medical Information Call Center at 1-800-462-3636.

3. After removing the flip-off cap from each vial, using aseptic technique swab the rubber stopper and surrounding surface of the vial containing XIAFLEX® and the vial containing the diluent for reconstitution with sterile alcohol (no other antiseptics should be used). Use only the supplied diluent for reconstitution. The diluent contains calcium, which is required for the activity of XIAFLEX®.

4. Using a 1-mL syringe with 0.01-mL graduations with a 27-gauge ½-inch needle (not supplied), withdraw a volume of 0.39 mL of the diluent supplied.

5. Inject the diluent slowly into the sides of the vial containing the lyophilized powder of XIAFLEX®.

6. Do not invert the vial or shake the solution. Slowly swirl the solution to ensure that all of the lyophilized powder has gone into the solution. Do not use if opaque particles, discoloration, or other foreign particles are present.

7. The reconstituted XIAFLEX® solution is now ready for injection.
8. The reconstituted XIAFLEX® solution can be kept at room temperature (20°C to 25°C [68°F to 77°F]) for up to 1 hour or refrigerated at 2°C to 8°C (36°F to 46°F) for up to 4 hours prior to administration. If the reconstituted XIAFLEX® solution is refrigerated, allow the solution to return to room temperature for approximately 15 minutes before use and no longer than 60 minutes.

9. Do not recap the needle. Discard the syringe, needle, and diluent used for reconstitution using medical waste disposal procedures.

### Self-Test Questions

1. Before use, for how long should the vials containing XIAFLEX® and the diluent be left to stand at room temperature?
   - a) Five to ten minutes
   - b) At least fifteen but no more than sixty minutes
   - c) Sixty to ninety minutes
   - d) At least two hours

2. The amount of diluent that should be used for reconstituting the lyophilized powder of XIAFLEX® is:
   - a) 0.15 mL
   - b) 0.25 mL
   - c) 0.31 mL
   - d) 0.39 mL

3. The reconstituted XIAFLEX® solution can be kept at room temperature for up to 1 hour or refrigerated for up to:
   - a) Two hours
   - b) Three hours
   - c) Four hours
   - d) Five hours
Identifying the Treatment Area and Injecting XIAFLEX®

This section outlines the procedures for identifying the treatment area and injecting the reconstituted XIAFLEX® solution into the Peyronie’s plaque.

NOTE: Prior to administering XIAFLEX® and as part of every treatment-related visit, use the Patient Counseling Tool, What You Need to Know About XIAFLEX® Treatment for Peyronie’s Disease: A Patient Guide, to discuss important information with each patient. Patients should be given this counseling tool to take home for reference along with a Medication Guide. See page 24 for details.

Identifying the Treatment Area

Prior to each treatment cycle, identify the treatment area as follows:

1. Induce a penile erection. A single intracavernosal injection of 10 mcg or 20 mcg of alprostadil may be used for this purpose. Apply antiseptic at the site of injection and allow the skin to dry prior to the intracavernosal injection.

2. Locate the plaque at the point of maximum concavity (or focal point) in the bend of the penis.

Answers to Self-Test Questions

1. Before use, for how long should the vials containing XIAFLEX® and the diluent be left to stand at room temperature?
   
   a) Five to ten minutes  
   b) At least fifteen but no more than sixty minutes  
   c) Sixty to ninety minutes  
   d) At least two hours

2. The amount of diluent that should be used for reconstituting the lyophilized powder of XIAFLEX® is:
   
   a) 0.15 mL  
   b) 0.25 mL  
   c) 0.31 mL  
   d) 0.39 mL

3. The reconstituted XIAFLEX® solution can be kept at room temperature for up to 1 hour or refrigerated for up to:
   
   a) Two hours  
   b) Three hours  
   c) Four hours  
   d) Five hours
Injection Procedure

The reconstituted XIAFLEX® solution should be clear. Inspect the solution visually for particulate matter and discoloration prior to administration. If the solution contains particulates, is cloudy, or is discolored, do not inject the reconstituted solution.

1. Apply antiseptic at the site of the injection and allow the skin to dry. Administer suitable local anesthetic, if desired.

2. Using a new hubless syringe containing 0.01-mL graduations with a permanently fixed 27-gauge ½-inch needle (not supplied), withdraw a volume of 0.25 mL of reconstituted solution (containing 0.58 mg of XIAFLEX®). There will be reconstituted solution left in the vial.

3. The penis should be in a flaccid state before XIAFLEX® is injected. Place the needle tip on the side of the target plaque in alignment with the point of maximal concavity. Orient the needle so that it enters the plaque from the side, NOT downwards or perpendicularly towards the corpora cavernosum.

4. Insert and advance the needle transversely through the width of the plaque, towards the opposite side of the plaque without passing completely through it. Proper needle position is confirmed by carefully noting resistance to minimal depression of the syringe plunger.

5. With the tip of the needle placed within the plaque, initiate the injection, maintaining steady pressure to slowly inject the drug into the plaque. Withdraw the needle slowly, so as to deposit the full dose along the needle track within the plaque. For plaques that are only a few millimeters in width, the distance of withdrawal of the syringe may be very minimal. The goal is always to deposit the full dose entirely within the plaque.
6. Upon complete withdrawal of the needle, apply gentle pressure at the injection site. Apply a dressing as necessary.

7. Discard the unused portion of the reconstituted solution and diluent after each injection. Do not store, pool, or use any vials containing unused reconstituted solution or diluent.

8. The second injection of each treatment cycle should be made approximately 2 mm to 3 mm apart from the first injection and within the plaque.

At each patient visit, counsel the patient as appropriate on the following:

- The risks of penile fracture and other serious injury to the penis
- That the patient’s penis may appear bruised and/or swollen
- That the patient may have mild-to-moderate penile pain that can be relieved by taking over-the-counter pain medications
- To promptly contact the physician if, at any time, the patient has any of these symptoms:
  - Severe purple bruising and swelling of the penis
  - Severe pain in the penis
  - A popping sound or sensation in an erect penis
  - Sudden loss of the ability to maintain an erection
  - Difficulty urinating or blood in the urine
  
  These symptoms may indicate penile fracture, and may require surgery.

- To return to the healthcare provider’s office when directed for further injection(s) and/or penile modeling procedure(s)
- To not have sex between the first and second injections of a treatment cycle
- To wait at least 4 weeks after the second injection of a treatment cycle before resuming sexual activity, provided pain and swelling have subsided
- To perform gentle, at-home modeling activities, as recommended by the physician
- To refrain from using a vacuum erection device during treatment with XIAFLEX®
- To avoid abdominal straining associated with situations, such as straining during bowel movements

**Self-Test Questions**

1. The proper site of injection for XIAFLEX® is:
   a) Laterally into the distal two-thirds of the penis
   b) At the point of minimal concavity in the bend of the penis
   c) At the point of maximal concavity in the bend of the penis
   d) Two millimeters from the base of the erect penis

2. The amount of reconstituted XIAFLEX® that should be injected into the Peyronie's plaque is:
   a) 0.20 mL
   b) 0.25 mL
   c) 0.31 mL
   d) 0.39 mL

3. When marking the treatment area the penis should be:
   a) Flaccid
   b) Erect

4. When injecting XIAFLEX® the penis should be:
   a) Flaccid
   b) Erect

5. The needle needs to be inserted in which direction into the plaque?
   a) Perpendicular to
   b) Transversely through the width of
   c) Parallel to
   d) Adjacent to, but not within

6. The goal of injection is always to deposit the full dose of drug:
   a) Entirely within the plaque
   b) Mostly within the plaque
   c) Entirely outside of the plaque
   d) Both inside and outside of the plaque
Answers to Self-Test Questions

1. The proper site of injection for XIAFLEX® is:
   a) Laterally into the distal two-thirds of the penis
   b) At the point of minimal concavity in the bend of the penis
   c) At the point of maximal concavity in the bend of the penis
   d) Two millimeters from the base of the erect penis

2. The amount of reconstituted XIAFLEX® that should be injected into the Peyronie’s plaque is:
   a) 0.20 mL
   b) 0.25 mL
   c) 0.31 mL
   d) 0.39 mL

3. When marking the treatment area the penis should be:
   a) flaccid
   b) erect

4. When injecting XIAFLEX® the penis should be:
   a) flaccid
   b) erect

5. The needle needs to be inserted in which direction into the plaque?
   a) Perpendicular to
   b) Transversely through the width of
   c) Parallel to
   d) Adjacent to, but not within

6. The goal of injection is always to deposit the full dose of drug:
   a) Entirely within the plaque
   b) Mostly within the plaque
   c) Entirely outside of the plaque
   d) Both inside and outside of the plaque

Penile Modeling (In-Office and At-Home)

This section outlines the in-office penile modeling procedure, which, in conjunction with XIAFLEX®, helps relieve curvature deformity and straighten the penile shaft. At a follow-up visit 1 to 3 days after the second injection of each treatment cycle, perform a penile modeling procedure (as described below) on the flaccid penis to stretch and elongate the treated plaque.

This section also outlines instructions to give to patients on how to perform daily, at-home penile modeling activities for 6 weeks following each treatment cycle.

NOTE: Prior to administering XIAFLEX® and as part of every treatment-related visit, use the Patient Counseling Tool, What You Need to Know About XIAFLEX® Treatment for Peyronie’s Disease: A Patient Guide, to discuss important information with each patient. See page 24 for details.

In-Office Penile Modeling Procedure

1. Administer suitable local anesthetic, if desired.

2. Wearing gloves, grasp the plaque or indurated portion of the flaccid penis about 1 cm proximal and distal to the injection site. Avoid direct pressure on the injection site.

3. Using the target plaque as a fulcrum point, use both hands to apply firm, steady pressure to elongate and stretch the plaque. The goal is to gradually create bending opposite to the patient’s penile curvature, with stretching to the point of moderate resistance.

Dorsal plaque being modeled

4. Hold pressure for 30 seconds, then release.

5. After a 30-second rest period, repeat the penile modeling technique for a total of 3 modeling attempts at 30 seconds for each attempt.
At-Home Penile Modeling Activities

There are 2 types of at-home penile modeling activities. One is a gentle stretching activity; the other is a gentle straightening activity. Discuss with patients the best time to perform these activities. Patients will do these for approximately 6 weeks after each treatment cycle.

Patients should perform the penis-stretching activity daily, three times per day, with a nonerect penis.

For the **stretching activity**, instruct the patient to:

1. Grasp the tip of the penis with the fingers of one hand and hold the base of the penis with the fingers of the other.
2. Gently pull the penis away from the body to its full length.
3. Hold the stretch for 30 seconds.
4. Let go and allow the penis to return to its normal, unstretched length.

Patients should perform the penis-straightening activity no more than once per day only if a spontaneous erection occurs. If the patient does not have a spontaneous erection, he should not attempt the penis straightening.

For the **straightening activity**, instruct the patient to:

1. Gently attempt to bend the shaft of the erect penis in the opposite direction of the curve, but not so forcefully as to produce significant pain or discomfort.
2. Hold the penis in this more straightened position for 30 seconds, then let go.
3. Perform this no more than once per day, if a spontaneous erection unrelated to sexual activity occurs.
Self-Test Questions

1. How soon should the in-office penile modeling procedure be performed after the second injection of each treatment cycle?
   a) Immediately
   b) Fifteen to sixty minutes
   c) One to three days
   d) Five to seven days

2. When performing in-office penile modeling procedure, hold the pressure for thirty seconds and rest for thirty seconds for a total of:
   a) Two times
   b) Three times
   c) Five times
   d) Ten times

3. The patient should be instructed to perform at-home penile straightening activity on a spontaneous erection unrelated to sexual activity no more than once daily for thirty seconds. How often should the patient perform the stretching activity on the flaccid penis?
   a) At no time
   b) Once daily for a total of one minute
   c) Five times daily for thirty seconds at a time
   d) Three times daily for thirty seconds at a time

Answers to Self-Test Questions

1. How soon should the in-office penile modeling procedure be performed after the second injection of each treatment cycle?
   a) Immediately
   b) Fifteen to sixty minutes
   c) One to three days
   d) Five to seven days

2. When performing in-office penile modeling procedure, hold the pressure for thirty seconds and rest for thirty seconds for a total of:
   a) Two times
   b) Three times
   c) Five times
   d) Ten times

3. The patient should be instructed to perform at-home penile straightening activity on a spontaneous erection unrelated to sexual activity no more than once daily for thirty seconds. How often should the patient perform the stretching activity on the flaccid penis?
   a) At no time
   b) Once daily for a total of one minute
   c) Five times daily for thirty seconds at a time
   d) Three times daily for thirty seconds at a time
Patient Counseling

A Patient Counseling Tool is a part of the XIAFLEX® REMS Program. This Tool, called What You Need to Know About XIAFLEX® Treatment for Peyronie’s Disease: A Patient Guide, must be given to the patient at each visit. The Tool contains the following information that you should discuss with each patient:

• The risks of corporal rupture (penile fracture) and other serious penile injury
• Precautions related to the patient’s actions to reduce these adverse outcomes
  o Advising patients to not have sex between the first and second injections of a treatment cycle
  o Wait at least four weeks after the second injection of a treatment cycle before resuming sexual activity
  o Do not use a vacuum erection device during treatment
  o Avoid activities that may cause straining of the abdominal muscles, such as straining during bowel movements
• Symptoms to look for and conditions under which patients should promptly contact their healthcare provider
• Clear instructions on at-home penile modeling activities

The patient must be given a copy of the Patient Counseling Tool to take home.

In addition, provide a Medication Guide to each patient prior to each injection of XIAFLEX®.

To obtain copies of the Patient Counseling Tool,
• Visit www.XIAFLEXREMS.com
• Call 1-877-313-2135
• Or contact your XIAFLEX® sales representative

Convenient tear pads are also available for your office.

Self-Test Questions

1. A Peyronie’s patient receiving XIAFLEX® should be advised to wait how long following the second injection of each treatment cycle before resuming sexual activity?
   a) 1-2 days
   b) 2 weeks
   c) 4 weeks
   d) 2 months

2. True or False. The Patient Counseling Tool, “What You Need to Know About XIAFLEX® Treatment for Peyronie’s Disease: A Patient Guide,” must be given to the patient at EACH treatment visit.
   a) True
   b) False

3. True or False. The Medication Guide should be provided to each patient PRIOR to EACH injection of XIAFLEX®.
   a) True
   b) False
Answers to Self-Test Questions

1. A Peyronie’s patient receiving XIAFLEX® should be advised to wait how long following the second injection of each treatment cycle before resuming sexual activity?

   a) 1-2 days
   b) 2 weeks
   c) 4 weeks
   d) 2 months

2. True or False. The Patient Counseling Tool, “What You Need to Know About XIAFLEX® Treatment for Peyronie’s Disease: A Patient Guide,” must be given to the patient at EACH treatment visit.

   a) True
   b) False

3. True or False. The Medication Guide should be provided to each patient PRIOR to EACH injection of XIAFLEX®.

   a) True
   b) False


Contact Us

For more information about the XIAFLEX® REMS Program, call 1-877-313-1235.

If you have product-related questions or to report adverse events, please contact the XIAFLEX® Medical Information Call Center at 1-800-462-3636. Adverse events may also be reported to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
### XIAFLEX® REMS Video (Peyronie’s Disease)

<table>
<thead>
<tr>
<th>VISUAL</th>
<th>AUDIO</th>
</tr>
</thead>
</table>
| **TITLE FRAME** | **VO:** Welcome to the REMS training video for administering XIAFLEX® for Peyronie’s disease. A REMS is a strategy to manage known or potential risks associated with a drug, and is required by the FDA to ensure that the benefits of the drug outweigh its risks. XIAFLEX®, or collagenase clostridium histolyticum, is indicated for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least thirty degrees at the start of therapy [Ref: PI/p.3/§1/¶ 2]. XIAFLEX® is only available under a restricted distribution program called the XIAFLEX® REMS because of the risks of penile fracture and other serious penile injury associated with using XIAFLEX® in treating Peyronie’s disease. This training video is part of the XIAFLEX® REMS program. This video discusses:  
• The steps necessary to prepare and administer XIAFLEX®  
• The in-office penile modeling procedure that is part of each XIAFLEX® treatment cycle  
• The daily, at-home penile modeling activities  
• Counseling your patient with the XIAFLEX® Patient Counseling Tool  
XIAFLEX® is also indicated for the treatment of adult patients with Dupuytren’s contracture with a palpable cord. [Ref: PI/p.3/§1/¶ 1] |

**ON-SCREEN COPY:** REMS training video for administering XIAFLEX® for Peyronie’s disease.

**VISUAL:** REMS description scrolls

A REMS is a strategy to manage known or potential risks associated with a drug, and is required by the FDA to ensure that the benefits of the drug outweigh its risks.

XIAFLEX®, or collagenase clostridium histolyticum, is indicated for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least thirty degrees at the start of therapy.

XIAFLEX® is only available under a restricted distribution program called the XIAFLEX® REMS because of the risks of penile fracture and other serious penile injury associated with using XIAFLEX® in treating Peyronie’s disease.

This training video is part of the XIAFLEX® REMS program. This video discusses:

• The steps necessary to prepare and administer XIAFLEX®
• The in-office penile modeling procedure that is part of each XIAFLEX® treatment cycle
• The daily, at-home penile modeling activities
that are performed for approximately 6 weeks after each treatment cycle

- Counseling your patient with the XIAFLEX®
  Patient Counseling Tool

XIAFLEX® is also indicated for the treatment of adult patients with Dupuytren’s contracture with a palpable cord. [Ref: PI/p.3/§1/¶ 1]

XIAFLEX® (collagenase clostridium histolyticum)
© 2018 Endo Pharmaceuticals Inc.
All rights reserved

Frame 1

**VISUAL:** REMS headline fades away and XIAFLEX® logo moves to center of screen.

**ON-SCREEN COPY:** XIAFLEX®
collagenase clostridium histolyticum

www.XIAFLEXREMS.com.

**VO:**
For the treatment of Peyronie’s disease, XIAFLEX® should be administered by a healthcare provider experienced in the treatment of male urological diseases who has completed the required training. [Ref: PI/p.6/§2.2/¶ 1]

This video demonstrates the steps necessary to prepare and administer XIAFLEX®. It also describes the in-office penile modeling procedure that is part of each XIAFLEX®
treatment cycle, as well as the daily, at-home penile modeling activities that are performed for approximately six weeks after each cycle. [Ref: PI/p.9/§2.2/Penile Modeling for PD/¶1; PI/p.9/§2.2/Penile Modeling for PD/¶2] It also includes directions for utilizing the XIAFLEX®
INTRODUCTION

Frame 2

**Visual:** Cut to cross-section illustration of penis with callouts for Peyronie’s plaque and tunica albuginea

**On-Screen Copy:** Peyronie’s plaque; Tunica albuginea

**VO:**

Peyronie’s disease is a localized connective tissue disorder characterized by changes in collagen composition in the tunica albuginea. [Ref: Hellstrom, p. 397/col 1/¶2/lines 1-4] These changes cause an abnormal scar formation known as Peyronie’s plaque, which is typically a palpable bump under the skin. [Ref: Ralph, p 1, col 1, ¶1, lines 6-7; Ref: Moreland, p.408/col 2/¶1; Ref: Bella/p. 1529/col 1/¶2/lines 10-11] The Peyronie’s plaque is composed predominantly of collagen, and replaces the normally elastic fibers of the tunica albuginea. [Ref: CSR/p.14/¶1/lines 2-3]

Microvascular trauma resulting from excessive bending or injury to the erect penis (possibly during sexual activity) is thought to be an important trigger for the inflammatory response and plaque development characteristic of Peyronie’s disease. [Ref 3:Moreland, p.407/col 2/¶2; p.408/col.1/¶1] Genetic predisposition and autoimmunity may also play a role in its development. [Moreland, p.406/col 2/¶2/lines 3-8; lines 21-31]

Frame 3

**Visual:** Animation changes perspective to illustrate penis profile with Peyronie’s plaque causing curvature

**On-Screen Copy:** Peyronie’s plaque

**VO:**

One of the hallmarks of Peyronie’s disease is curvature deformity. Peyronie’s disease may also cause other types of deformities, including narrowing, indentation, and shortening of the penis. [Ref 4: Bella/p. 1527/col 1/¶1/lines 4-8]
### Frame 4

**ON-SCREEN COPY:** XIAFLEX®
collagenase clostridium histolyticum

**Mechanism of Action**

**VO:**
XIAFLEX® contains two different types of purified collagenase clostridium histolyticum in a defined mass ratio. [Ref: PI/p.19/§11/¶1]

### Frame 5

**VISUAL:** Animation illustrates enzymatic disruption of the collagen found in Peyronie’s plaque

**VO:**
Injection of XIAFLEX® into a Peyronie’s plaque, which is composed mostly of collagen, may result in enzymatic disruption of the collagen found in Peyronie’s plaque.

[Ref: PI/p.20/§12.1/¶3, lines 1-3]

### Frame 6

**VISUAL:** Transition to full male figure

**VO:**
Following this disruption of the collagen-containing plaque, penile curvature deformity may improve and Patient-Reported Bother may be reduced.

[Ref: PI/p.20/12.1/¶3/lines 2-4]
<table>
<thead>
<tr>
<th>Frame 7</th>
<th>Frame 8</th>
</tr>
</thead>
</table>
| **ON-SCREEN COPY:** XIAFLEX® collagenase clostridium histolyticum Treatment Overview and Risk of Penile Injuries | **VO:** XIAFLEX® should be administered by a healthcare provider experienced in the treatment of male urological diseases who has completed the required training. [Ref: PI/p.6/§2.2/¶1]

XIAFLEX®, supplied as a lyophilized powder, must be reconstituted with the provided diluent prior to use. [Ref: PI/p.7/§2.2/¶2/lines 1-2] The dose of XIAFLEX® is 0.58 mg per injection administered into a Peyronie’s plaque. If more than one plaque is present, inject into the plaque causing the curvature deformity. [Ref: PI/p.7/§2.2/¶2/lines 2-4]

Injection of XIAFLEX® into collagen-containing structures such as the corpora cavernosa of the penis may result in damage to those structures and possible injury such as corporal rupture (penile fracture). Therefore, XIAFLEX® should be injected only into the Peyronie’s plaque and care should be taken to avoid injecting into the urethra, nerves, blood vessels, corpora cavernosa or other collagen-containing structures of the penis.

Healthcare providers must counsel patients on the risks of penile fractures or other serious injuries of the penis that can occur with XIAFLEX® treatment, such as penile hematoma, ecchymosis, swelling, and pain.

| **Frame 8** | **VO:** An entire treatment course of XIAFLEX® consists of up to four treatment cycles and takes approximately 24 weeks to complete. Each treatment cycle consists of four steps:

- The first XIAFLEX® injection procedure
- The second XIAFLEX® injection procedure
  - The second XIAFLEX® injection procedure occurs one to three days after the first injection procedure.
- One in-office penile modeling procedure. |
TREATMENT OVERVIEW AND RISK OF PENILE INJURIES

ON-SCREEN COPY: One XIAFLEX® Treatment Cycle (diagram)

If the curvature deformity is less than 15 degrees after the 1st, 2nd or 3rd Treatment Cycle, or if you determine that further treatment is not clinically indicated, then subsequent treatment cycles should not be administered.

The safety of more than one treatment course of XIAFLEX® is not known.

- The in-office penile modeling procedure is performed one to three days after the second injection procedure of each treatment cycle.

And daily patient penile modeling at home
- Six weeks of daily, at-home penile modeling activities after the in-office penile modeling procedure. (Patients must be counseled on how to perform the at-home modeling activities as appropriate.)

If the curvature deformity is less than 15 degrees after the first, second, or third treatment cycle, or if you determine that further treatment is not clinically indicated, then the subsequent treatment cycles should not be administered. The safety of more than one treatment course of XIAFLEX® is not known. [Ref: PI/p.7/§2.2/¶1-3]
In this section, we will explain the procedure for reconstitution of the lyophilized powder of XIAFLEX®.

**VO:**

XIAFLEX®, supplied as a lyophilized powder, must be reconstituted with the provided diluent prior to use. XIAFLEX® is supplied in single-use glass vials containing 0.9 mg of collagenase clostridium histolyticum as a sterile, lyophilized powder for reconstitution. [Ref: PI/p.10/§3]

**VO:**

Sterile diluent for reconstitution is provided in the package in a single-use glass vial containing 3 mL of 0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride. XIAFLEX® must be reconstituted with the provided diluent prior to use. [Ref: PI/p.10/§3]
**Frame 12**

**VISUAL:** XIAFLEX® vial; Sterile diluent vial; temperature gauge illustrating 2°C to 8°C and 36°F to 46°F

**ON-SCREEN COPY:** Prior to Reconstitution
Store in refrigerator

**VO:**

The vials of lyophilized XIAFLEX® powder and sterile diluent should be stored in a refrigerator at two to eight degrees Celsius or thirty-six to forty-six degrees Fahrenheit. Do not freeze.

[Ref: PI/p.31/§16/¶1]

**Frame 13**

**VISUAL:** XIAFLEX® vial; Sterile diluent vial

**ON-SCREEN COPY:** After refrigeration, let the vial containing XIAFLEX® and the vial containing diluent stand at room temperature for at least 15 minutes before use
No longer than 60 minutes

**VO:**

Before use, remove the vial containing the lyophilized powder of XIAFLEX® and the vial containing the diluent for reconstitution from the refrigerator and check the labels on both the diluent vial and the lyophilized powder vial to make sure they have not expired. Allow the two vials to stand at room temperature for at least fifteen minutes and no longer than sixty minutes

[Ref: PI/p.7/§2.2/bullet a, lines 1-4]
### Frame 14

**Visual:** Two XIAFLEX® vials one intact, one eroded

**On-screen Copy:** INTACT; ERODED
If eroded, call 1-800-462-3636

**VO:**
Visually inspect the vial containing XIAFLEX®. The cake of lyophilized powder should be intact and white in color. If the cake has been eroded, it should not be used, and should be reported to the XIAFLEX® Medical Information Center by calling 1-800-462-3636.  
[Ref: PI/p.7/§2.2/bullet a, lines 4-5]

### Frame 15

**Visual:** Gloved hands remove flip-off cap from XIAFLEX® vial

**VO:**
After removing the flip-off cap from each vial, using aseptic technique, swab the rubber stopper and surrounding surface of the vial containing XIAFLEX® and the vial containing the diluent for reconstitution with sterile alcohol.  
[Ref: PI/p.8/§2.2/bullet b]

### Frame 16

**VO:**
No other antiseptics should be used.  
[Ref: PI/p.8/§2.2/bullet b] Use only the supplied diluent for reconstitution. The diluent contains calcium, which is required for the activity of XIAFLEX®.  
[Ref: PI/p.8/§2.2/bullet c]
**VISUAL:** Gloved hands remove flip-off cap from diluent vial

**Frame 17**

Use a 1-mL syringe with 0.01-mL graduations and a 27-gauge ½-inch needle to withdraw a volume of 0.39 mL of the diluent supplied.

**VISUAL:** Gloved hands hold 1-mL syringe with 0.01-mL graduations and a 27-gauge ½-inch needle to withdraw diluent

**ON-SCREEN COPY:** Use a 1-mL syringe with 0.01-mL graduations and a 27-gauge ½-inch needle to withdraw a volume of 0.39 mL of the diluent supplied

**VO:**
Using a 1-mL syringe with 0.01-mL graduations with a twenty-seven-gauge one-half-inch needle, which is not supplied, withdraw a volume of 0.39 mL of the diluent supplied. [Ref: PI/p.8/§2.2/bullet d]
**VISUAL:** Gloved hands hold 1-mL syringe and inject diluent slowly into sides of XIAFLEX® vial

**ON-SCREEN COPY:** Inject the diluent slowly into the sides of the XIAFLEX® vial. Do not invert the vial or shake the solution.

**Frame 19**

**VISUAL:** Gloved hands slowly swirl the solution

**ON-SCREEN COPY:** Slowly swirl the solution to ensure that all of the lyophilized powder has gone into solution.

**VO:**
> Do not invert the vial or shake the solution. Slowly swirl the solution to ensure that all of the lyophilized powder has gone into solution. Do not use if opaque particles, discoloration, or other foreign particles are present. [Ref: PI/p.8/§2.2/bullet e/lines 2-3]

**Frame 20**

**VO:**
**VISUAL:** Gloved hand holds vial of reconstituted XIAFLEX® solution

The XIAFLEX® solution is now ready for injection.

**Frame 21**

**VISUAL:** Vial with reconstituted XIAFLEX®; clock illustrating 15-minute duration; clock animates to 60 minutes, illustrating the VO “and no longer than 60 minutes”

**ON-SCREEN COPY:** Reconstituted XIAFLEX® After refrigeration, let stand at room temperature for 15 minutes before use

**VO:**

The reconstituted XIAFLEX® solution can be kept at room temperature of twenty to twenty-five degrees Celsius, or sixty-eight to seventy-seven degrees Fahrenheit, for up to one hour; or refrigerated at two to eight degrees Celsius, or thirty-six to forty-six degrees Fahrenheit, for up to four hours prior to administration. If the reconstituted XIAFLEX® solution is refrigerated, allow this solution to return to room temperature for approximately fifteen minutes before use and no longer than sixty minutes.

[Ref: PI/p.8/§2.2/bullet f]

**Frame 22**

**VO:**

As a final step, discard the syringe, needle and diluent used for reconstitution using medical waste disposal procedures. [Ref: PI/p.8/§2.2/bullet g]
**PREPARATION FOR ADMINISTRATION**

<table>
<thead>
<tr>
<th>VISUAL: Gloved hand discards syringe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frame 23</td>
</tr>
</tbody>
</table>
| **XIAFLEX®**
collagenase clostridium histolyticum|
| Self-Test Questions                |
| **ON-SCREEN COPY:** XIAFLEX®
collagenase clostridium histolyticum|
| Self-Test Questions                |

**VO:**
This completes the section on XIAFLEX® preparation for administration. To confirm understanding of the key points of this section, please answer the following self-test questions. After answering these questions correctly, you may continue to the next section.
Before use, for how long should the vials containing XIAFLEX® and the diluent be left to stand at room temperature?

- **a)** Five to ten minutes
- **b)** At least fifteen but no more than sixty minutes
- **c)** Sixty to ninety minutes
- **d)** At least two hours

**VO:**

b) At least fifteen but no more than sixty minutes [Ref: PI/p.8/§2.2/bullet f]
Frame 26  
**VISUAL:** Question appears on-screen and answers appear sequentially, corresponding to VO  
**ON-SCREEN COPY:** The amount of diluent that should be used for reconstituting the lyophilized powder of XIAFLEX® is:  
- a) 0.15 mL  
- b) 0.25 mL  
- c) 0.31 mL  
- d) 0.39 mL  

**VO:**  
The amount of diluent that should be used for reconstituting the lyophilized powder of XIAFLEX® is:  
- a) 0.15 mL  
- b) 0.25 mL  
- c) 0.31 mL  
- d) 0.39 mL  

Frame 26A  
**VISUAL:** The correct answer is highlighted. **ON-SCREEN COPY:** The amount of diluent that should be used for reconstituting the lyophilized powder of XIAFLEX® is:  
- a) 0.15 mL  
- b) 0.25 mL  
- c) 0.31 mL  
- d) **0.39 mL**  

**VO:**  
d) **0.39 mL** [Ref: PI/p.8/§2.2/bullet d]  

Frame 27  
**VISUAL:** Question appears on screen and answers appear sequentially, corresponding to VO  
**ON-SCREEN COPY:** The reconstituted XIAFLEX® solution can be kept at room temperature for up to 1 hour or refrigerated for up to:  
- a) 2 hours  
- b) 3 hours  
- c) 4 hours  
- d) 5 hours  

**VO:**  
The reconstituted XIAFLEX® solution can be kept at room temperature for up to 1 hour or refrigerated for up to:  
- a) Two hours  
- b) Three hours  
- c) Four hours  
- d) Five hours
**Frame 27A**

**VISUAL:** The correct answer is highlighted. 

**ON-SCREEN COPY:** The reconstituted XIAFLEX® solution can be kept at room temperature for up to 1 hour or refrigerated for up to:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>a)</td>
<td>2 hours</td>
</tr>
<tr>
<td>b)</td>
<td>3 hours</td>
</tr>
<tr>
<td>c)</td>
<td>4 hours</td>
</tr>
<tr>
<td>d)</td>
<td>5 hours</td>
</tr>
</tbody>
</table>

**VO:**

c) **four hours** [Ref: PI/p.8/§2.2/bullet f]
**IDENTIFYING THE TREATMENT AREA AND INJECTING XIAFLEX**

| Frame 28 | VO: We will now discuss the proper procedures for identifying the treatment area and injecting the reconstituted XIAFLEX® (collagenase clostridium histolyticum) solution into the Peyronie’s plaque.

Prior to administering XIAFLEX® and as part of every treatment-related visit, use the Patient Counseling Tool to discuss important information with each patient. |
| --- | --- |

**ON-SCREEN COPY:** XIAFLEX®
collagenase clostridium histolyticum
Identifying the Treatment Area and Injecting XIAFLEX®

| Frame 29 | VO: Prior to each treatment cycle, identify the treatment area as follows: Induce a penile erection. A single intracavernosal injection of ten micrograms or twenty micrograms of alprostadil may be used for this purpose. Apply antiseptic at the site of injection and allow the skin to dry prior to the intracavernosal injection.  
[Ref: PI/p.8/§2.2/ID of Tx Area for PD, bullet a, sub-bullet 1] |
| --- | --- |

**VISUAL:** Gloved hand identifies the treatment area and induces an erection
## IDENTIFYING THE TREATMENT AREA AND INJECTING XIAFLEX

<table>
<thead>
<tr>
<th>Frame 30</th>
<th><strong>VO:</strong> Locate the plaque at the point of maximum concavity, or focal point, in the bend of the penis. [Ref: PI/p.8/§2.2/ID of Tx Area for PD, bullet a, sub-bullet 2] Mark the point with a surgical marker. This indicates the target area in the plaque for XIAFLEX® deposition. [Ref: PI/p.8/§2.2/ID of Tx Area for PD, bullet a, sub-bullet 3]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VISUAL:</strong> Gloved hands locate the plaque at point of maximum concavity and mark the focal point with a surgical marker</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Frame 31</th>
<th><strong>VO:</strong> The reconstituted XIAFLEX® solution should be clear. Inspect the solution visually for particulate matter and discoloration prior to administration. If the solution contains particulates, is cloudy, or is discolored, do not inject the reconstituted solution. [Ref: PI/p.8/§2.2/Inj Procedure for PD/bullet a]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VISUAL:</strong> Gloved hand holds up vial for inspection</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Frame 32</th>
<th><strong>VO:</strong> Apply antiseptic at the site of the injection and allow the skin to dry. If desired, administer suitable local anesthetic. [Ref: PI/ p.8/§2.2/Inj Procedure for PD/bullets b,c]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VISUAL:</strong> Gloved hands apply antiseptic</td>
<td></td>
</tr>
</tbody>
</table>
IDENTIFYING THE TREATMENT AREA AND INJECTING XIAFLEX

**Frame 33**

**VISUAL:** Gloved hands with hubless 0.01-mL syringe withdraw fluid

**VO:**
Using a new hubless syringe containing 0.01-mL graduations with a permanently fixed twenty-seven-gauge half-inch needle, which is not supplied, withdraw a volume of 0.25 mL of reconstituted solution containing 0.58 mg of XIAFLEX®. There will be reconstituted solution remaining in the vial.  
[Ref: PI/p.8/§2.2/Inj Procedure for PD/bullet d]

**Frame 34**

**VISUAL:** Gloved hands orient the needle so that it enters the plaque from the side

**VO:**
The penis should be in a flaccid state before injecting XIAFLEX®. Place the needle tip on the side of the target plaque in alignment with the point of maximal concavity. Orient the needle so that it enters the plaque from the side, NOT downward or perpendicularly toward the body of the corpora cavernosum. [Ref: PI/p.8/§2.2/Inj Procedure for PD/bullet e]

**Frame 35**

**VISUAL:** Cut to needle insertion animation

**ON-SCREEN COPY:** Image not to scale

**VO:**
Insert and advance the needle transversely through the width of the plaque, toward the opposite side of the plaque and without passing completely through it. Proper needle position is confirmed by carefully noting resistance to minimal depression of the syringe plunger.  
[Ref: PI/p.9/§2.2/Inj Procedure for PD/bullet f]
<table>
<thead>
<tr>
<th>Frame 36</th>
<th><strong>VO:</strong> With the tip of the needle placed within the plaque, initiate the injection, maintaining steady pressure to slowly inject the drug into the plaque. Withdraw the needle slowly so as to deposit the full dose along the needle track within the plaque. For plaques that are only a few millimeters in width, the distance of withdrawal of the syringe may be very minimal. The goal is always to deposit the full dose entirely within the plaque. [Ref: PI/ p.9/§2.2/Inj Procedure for PD/bullet g]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VISUAL:</strong> Needle withdrawal animation; arrow indicates direction</td>
<td><strong>ON-SCREEN COPY:</strong> Image not to scale</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Frame 37</th>
<th><strong>VO:</strong> Upon complete withdrawal of the needle, apply gentle pressure at the injection site. Apply a dressing as necessary. [Ref: PI/ p.9/§2.2/Inj Procedure for PD/bullet h] Discard the unused portion of the reconstituted solution and diluent after each injection. Do not store, pool, or use any vials containing unused reconstituted solution or diluent. [Ref: PI/ p.9/§2.2/Inj Procedure for PD/bullet i]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VISUAL:</strong> A gloved hand applies pressure at the injection site</td>
<td></td>
</tr>
</tbody>
</table>
**Frame 38**

**VISUAL:** Gloved hand holds penis in place; copy and x’s appear, indicating injection sites 2-3 mm apart

**ON-SCREEN COPY:** 2-3 mm apart, but still within the plaque

**VO:**
The second injection of each treatment cycle should be made approximately two to three millimeters apart from the first injection and within the plaque. [Ref: PI/p.9/§2.2/Inj Procedure for PD/bullet j]

**Frame 39**

**ON-SCREEN COPY:** XIAFLEX® collagenase clostridium histolyticum

At each patient visit, counsel the patient as appropriate on the following:

- The risks of corporal rupture (penile fracture) and other serious injury to the penis
- That the patient’s penis may appear bruised and/or swollen [Ref: PI/p.32/§17.2/bullet 2]
- That the patient may have mild-to-moderate penile pain that can be relieved by taking over-the-counter pain medications [Ref: PI/p.32/§17.2/bullet 3]
- To promptly contact their physician if, at any time, they have any of these symptoms:
  - Severe purple bruising and swelling of the penis
  - Severe pain in the penis
  - A popping sound or sensation in an erect penis

**VO:**
To promptly contact the physician if, at any time, the patient has any of these symptoms:
– Sudden loss of the ability to maintain an erection
– Difficulty urinating or blood in the urine,
These symptoms may be accompanied by a popping or cracking sound from the penis

• To return to their healthcare provider’s office when directed for further injection(s) and/or penile modeling procedure(s)

• To not have sex between the first and second injections of a treatment cycle

• To wait at least four weeks after the second injection of a treatment cycle before resuming sexual activity, provided pain and swelling have subsided

• To perform gentle, at home modeling activities, as recommended by their physician.

• To refrain from using a vacuum erection device during treatment with XIAFLEX

• To avoid abdominal straining associated with situations, such as straining during bowel movements.

– Sudden loss of the ability to maintain an erection
– Difficulty urinating or blood in the urine,

These symptoms may indicate penile fracture, and may require surgery [Ref: PI/p.32/§17.2/bullet 4]

• To return to their healthcare provider’s office when directed for further injection(s) and/or penile modeling procedure(s) [Ref: PI/p.32/§17.2/bullet 5]

• To not have sex between the first and second injections of a treatment cycle

• To wait at least four weeks after the second injection of a treatment cycle before resuming sexual activity, provided pain and swelling have subsided [Ref: PI/p.32/§17.2/bullet 6]

• To perform gentle, at home modeling activities, as recommended by their physician.

• To refrain from using a vacuum erection device during treatment with XIAFLEX

• To avoid abdominal straining associated with situations, such as straining during bowel movements.
This completes the section on identifying the treatment area and injecting XIAFLEX®. To confirm understanding of the key points of this section, please answer the following self-test questions. After answering these questions, you may continue to the next section.
## IDENTIFYING THE TREATMENT AREA AND INJECTING XIAFLEX

<table>
<thead>
<tr>
<th>Frame 41</th>
<th>VO:</th>
</tr>
</thead>
</table>
| ON-SCREEN COPY:  XIAFLEX®
collagenase clostridium histolyticum
Self-Test Questions | SELF-TEST QUESTIONS |

<table>
<thead>
<tr>
<th>Frame 42</th>
<th>VO:</th>
</tr>
</thead>
</table>
| VISUAL: Question appears on-screen and answers appear sequentially, corresponding to VO
ON-SCREEN COPY: The proper site of injection for XIAFLEX® is:
a) Laterally into the distal two-thirds of the penis
b) At the point of minimal concavity in the bend of the penis
c) At the point of maximal concavity in the bend of the penis
d) 2 mm from the base of the erect penis | The proper site of injection for XIAFLEX® is:
a) Laterally into the distal two-thirds of the penis
b) At the point of minimal concavity in the bend of the penis
c) At the point of maximal concavity in the bend of the penis
d) Two millimeters from the base of the erect penis |

<table>
<thead>
<tr>
<th>Frame 42A</th>
<th>VO:</th>
</tr>
</thead>
</table>
| VISUAL: The correct answer is highlighted. ON-SCREEN COPY: The proper site of injection for XIAFLEX® is:
a) Laterally into the distal two-thirds of the penis
b) At the point of minimal concavity in the bend of the penis
c) At the point of maximal concavity in the bend of the penis
d) 2 mm from the base of the erect penis | c) At the point of maximal concavity in the bend of the penis [Ref: PI/p.8/§2.2/ID of Tx Area for PD, bullet a, sub-bullet 2] |
### Frame 43
**VISUAL:** Question appears on-screen and answers appear sequentially, corresponding to VO
**ON-SCREEN COPY:** The amount of reconstituted XIAFLEX® that should be injected into the Peyronie’s plaque is:
- a) 0.20 mL
- b) 0.25 mL
- c) 0.31 mL
- d) 0.39 mL

**VO:**
The amount of reconstituted XIAFLEX® that should be injected into the Peyronie’s plaque is:
- a) 0.20 mL
- b) 0.25 mL
- c) 0.31 mL
- d) 0.39 mL

### Frame 43A
**VISUAL:** The correct answer is highlighted.
**ON-SCREEN COPY:** The amount of reconstituted XIAFLEX® that should be injected into the Peyronie’s plaque is:
- a) 0.20 mL
- b) 0.25 mL
- c) 0.31 mL
- d) 0.39 mL

**VO:**
b) 0.25 mL [Ref: PI/p.8/§2.2/Inj Procedure for PD/bullet d]

### Frame 44
**VISUAL:** Question appears on-screen and answers appear sequentially, corresponding to VO
**ON-SCREEN COPY:** The penis should be _____ when marking the treatment area and _____ when injecting XIAFLEX®.
- a) Erect; erect
- b) Flaccid; flaccid
- c) Erect; flaccid
- d) Flaccid; erect

**VO:**
When marking the treatment area the penis should be
- (a) flaccid or (b) erect.

When injecting XIAFLEX® the penis should be:
- (a) flaccid or (b) erect.

### Frame 44A
**VISUAL:** Answers disappear and the correct answers are inserted into the question and highlighted.
**ON-SCREEN COPY:** The penis should be **erect** when marking the treatment area and **flaccid** when injecting XIAFLEX®.

**VO:**
The penis should be **erect** when marking the treatment area and **flaccid** when injecting XIAFLEX®.
[Ref: PI/p.8/§2.2/ID of Tx Area for PD/bullet a/sub-bullet 1]
[Ref: PI/p.8/§2.2/Inj Procedure for PD/bullet e/line 1]
<table>
<thead>
<tr>
<th>Frame 44</th>
<th>VO: When marking the treatment area should the penis be (a) flaccid or (b) erect?</th>
</tr>
</thead>
<tbody>
<tr>
<td>VISUAL: Question appears on-screen and answers appear sequentially, corresponding to VO</td>
<td></td>
</tr>
<tr>
<td>ON-SCREEN COPY: When marking the treatment area should the penis be (a) flaccid or (b) erect?</td>
<td></td>
</tr>
<tr>
<td>Frame 44A</td>
<td>VO: When marking the treatment area the penis should be erect. [Ref: PI/p.8/§2.2/ID of Tx Area for PD/bullet a/sub-bullet 1]</td>
</tr>
<tr>
<td>VISUAL: The correct answer is highlighted. ON-SCREEN COPY: When marking the treatment area should the penis be (a) flaccid or (b) erect</td>
<td></td>
</tr>
<tr>
<td>Frame 44B</td>
<td>VO: When injecting XIAFLEX® should the penis be: (a) flaccid or (b) erect?</td>
</tr>
<tr>
<td>VISUAL: Question appears on-screen and answers appear sequentially, corresponding to VO</td>
<td></td>
</tr>
<tr>
<td>ON-SCREEN COPY: When injecting XIAFLEX® should the penis be: (a) flaccid or (b) erect?</td>
<td></td>
</tr>
<tr>
<td>Frame 44C</td>
<td>VO: When injecting XIAFLEX® should the penis be: flaccid [Ref: PI/ p.8/§2.2/Inj Procedure for PD/bullet e/line 1]</td>
</tr>
<tr>
<td>VISUAL: Answers disappear and the correct answers are inserted into the question and highlighted. ON-SCREEN COPY: When injecting XIAFLEX® should the penis be: (a) flaccid or (b) erect?</td>
<td></td>
</tr>
<tr>
<td>Frame 45</td>
<td>VO: The needle needs to be inserted in which direction into the plaque?</td>
</tr>
<tr>
<td>VISUAL: Question appears on-screen and answers appear sequentially, corresponding to VO</td>
<td></td>
</tr>
<tr>
<td>ON-SCREEN COPY: The needle needs to be inserted ______ the plaque</td>
<td></td>
</tr>
<tr>
<td>a) Perpendicular to</td>
<td></td>
</tr>
<tr>
<td>b) Transversely through the width of</td>
<td></td>
</tr>
<tr>
<td>c) Parallel to</td>
<td></td>
</tr>
<tr>
<td>d) Adjacent to, but not within</td>
<td></td>
</tr>
<tr>
<td>Frame 45A</td>
<td>VO: The needle needs to be inserted <em>transversely through the width of</em> the plaque? [Ref: PI/p.9/§2.2/Inj Procedure for PD/bullet f/lines 1-2]</td>
</tr>
<tr>
<td>-----------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>VISUAL:</td>
<td>Answers disappear and the correct answer is inserted into the question and highlighted.</td>
</tr>
<tr>
<td>ON-SCREEN COPY:</td>
<td>The needle needs to be inserted <em>transversely through the width of</em> the plaque.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Frame 46</th>
<th>VO: The goal of injection is always to deposit the full dose of drug...</th>
</tr>
</thead>
<tbody>
<tr>
<td>VISUAL:</td>
<td>Question appears on-screen and answers appear sequentially, corresponding to VO</td>
</tr>
<tr>
<td>ON-SCREEN COPY:</td>
<td>The goal of injection is always to deposit the full dose of drug:</td>
</tr>
<tr>
<td></td>
<td>a) Entirely within the plaque</td>
</tr>
<tr>
<td></td>
<td>b) Mostly within the plaque</td>
</tr>
<tr>
<td></td>
<td>c) Entirely outside of the plaque</td>
</tr>
<tr>
<td></td>
<td>d) Both inside and outside of the plaque</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Frame 46A</th>
<th>VO: The goal of injection is always to deposit the full dose of drug <em>entirely within the plaque</em> [Ref: PI/p.9/§2.2/Inj Procedure for PD/bullet g/lines 5-6]</th>
</tr>
</thead>
<tbody>
<tr>
<td>VISUAL:</td>
<td>The correct answer is highlighted.</td>
</tr>
<tr>
<td>ON-SCREEN COPY:</td>
<td>The goal of injection is always to deposit the full dose of drug:</td>
</tr>
<tr>
<td></td>
<td>a) Entirely within the plaque</td>
</tr>
<tr>
<td></td>
<td>b) Mostly within the plaque</td>
</tr>
<tr>
<td></td>
<td>c) Entirely outside of the plaque</td>
</tr>
<tr>
<td></td>
<td>d) Both inside and outside of the plaque</td>
</tr>
</tbody>
</table>
In conjunction with XIAFLEX®, penile modeling helps improve curvature deformity and straighten the penile shaft. In this section, we will review the in-office penile modeling procedure that is performed one to three days following the second injection of XIAFLEX® in each treatment cycle. [Ref: PI/ p.9/§2.2/Penile Modeling Procedure/¶ 1] We will also review the at-home penile modeling activities that patients should be instructed to do daily. [Ref: PI/ p.9/§2.2/Penile Modeling for PD/¶ 2]

Prior to administering XIAFLEX® and as part of every treatment-related visit, use the Patient Counseling Tool to discuss important information with each patient.

At a follow-up visit one to three days after the second injection of each treatment cycle, perform the in-office penile modeling procedure on the flaccid penis in order to stretch and elongate the treated plaque. [Ref: PI/ p.9/§2.2/Penile Modeling for PD/¶ 1]
PENILE MODELING (IN-OFFICE AND AT-HOME)

procedure → 1 to 3 days → 2nd in-office injection procedure → 1 to 3 days → In-office penile modeling procedure

approximately 6 weeks; At-home penile modeling activities → Treatment Cycle 2; approximately 6 weeks; At-home penile modeling activities → Treatment Cycle 3; approximately 6 weeks; At-home penile modeling activities → Treatment Cycle 4; approximately 6 weeks; At-home penile modeling activities

Up to 4 treatment cycles may be administered

If the curvature deformity is less than 15 degrees after the 1st, 2nd or 3rd Treatment Cycle, or if you determine that further treatment is not clinically indicated, then subsequent treatment cycles should not be administered.

The safety of more than one treatment course of XIAFLEX® is not known.

Frame 49

VISUAL: Gloved hands grasp the plaque or indurated portion of the flaccid penis about 1 cm proximal and distal to the injection site.

VO:
If desired, administer suitable local anesthetic.
[Ref: PI/ p.9/§2.2/Penis Modeling Procedure/bullet 1]

Wearing gloves, grasp the plaque or indurated portion of the flaccid penis about one centimeter proximal and distal to the injection site. Avoid direct pressure on the injection site.
[Ref: PI/ p.9/§2.2/Penis Modeling Procedure/bullet 2]
### Frame 50

**VISUAL:** Gloved hands apply firm, steady pressure to elongate and stretch the plaque, creating bending opposite to the patient’s penile curvature

**ON-SCREEN COPY:**
- Use target plaque as fulcrum point
- Apply firm, steady pressure
- Gradually bend the shaft in the opposite direction of the curvature

**VO:**
Using the target plaque as a fulcrum point, use both hands to apply firm, steady pressure to elongate and stretch the plaque. The goal is to gradually create bending opposite to the patient’s penile curvature, with stretching to the point of moderate resistance.

[Ref: PI/p.9/§2.2/Penile Modeling Procedure/bullet 3]

Hold pressure for thirty seconds then release.

[Ref: PI/p.9/§2.2/Penile Modeling Procedure/bullet 3]

---

### Frame 51

**VISUAL:** Gloved hands repeat the penile modeling technique

**ON-SCREEN COPY:**
- Rest for 30 seconds
- Repeat a total of 3 times
- Hold for 30 seconds each time

**VO:**
After a thirty-second rest period, repeat the penile modeling technique for a total of three modeling attempts at thirty seconds each.

[Ref: PI/p.9/§2.2/Penile Modeling Procedure/bullet 4]
## PENILE MODELING (IN-OFFICE AND AT-HOME)

**Frame 52**

**On-Screen Copy:** XIAFLEX®

collagenase clostridium histolyticum

At-home Penile Modeling Activities

**VO:**

For the approximately six weeks following each treatment cycle, patients will need to perform the following penile modeling activities at home daily to help reduce penile curvature [Ref: PI/p.9/§2.2/Penile Modeling for PD/¶2]

<table>
<thead>
<tr>
<th>Frame 52A</th>
</tr>
</thead>
</table>

**VO:**

There are two types of home penis activities. One is a stretching activity. The other is a straightening activity. Be sure to instruct patients on exactly when to start the activities and how long to continue performing them. [Ref: PI/p.9/§2.2/Penile Modeling for PD/¶2]

The stretching activity should be performed three times daily and when the penis is not erect. Instruct patients to grasp the tip of the penis with the fingers of one hand and hold the base of the penis with the fingers of the other. Then, *gently* pull the penis away from the body to its full length. Hold the stretch for thirty seconds. Then let go and allow the penis to return to its normal unstretched length. [Ref: PI/p.10/§2.2/Penile Modeling for PD/bullet 2]

The penile straightening activity is performed a maximum of once per day on an erection unrelated to sexual activity. If the patient does not have a spontaneous erection, he should not attempt the penis straightening. Instruct patients to *gently* attempt to bend the shaft of the erect penis in the opposite direction of the curve, but not so forcefully as to produce significant pain or discomfort. Patients should hold the penis in this more straightened position for thirty seconds, then let go. [Ref: PI/p.10/§2.2/Penile Modeling for PD/bullet 1]
**VISUAL:** Animation demonstrates at-home patient stretching (first of three images above) and straightening (second and third images above) activities.

**Frame 53**

**ON-SCREEN COPY:**
Provide instructions on at-home penile modeling activities:
- On flaccid penis: Stretch 3 times daily for 30 seconds at a time
- On erect penis: Gently straighten and hold for 30 seconds, once daily

**VO:**
In summary, penis stretching is performed on a non-erect penis, three times a day for thirty seconds each time. Penis straightening is performed no more than once a day on a spontaneous erection unrelated to sexual activity. Discuss with patients the best time to perform these activities.

[Ref: PI/p.10/§2.2/Penile Modeling for PD/bullets 1-2]

**Frame 54**

**ON-SCREEN COPY:** XIAFLEX®
collagenase clostridium histolyticum
Self-Test Questions

**VO:**
This completes the section on the XIAFLEX® penile modeling, both in-office and at-home. To confirm understanding of the key points of this section, please answer the following self-test questions. After answering these questions, you may continue to the next section.
**PENILE MODELING (IN-OFFICE AND AT-HOME)**

<table>
<thead>
<tr>
<th>Frame 55</th>
<th>VISUAL: Question appears on-screen and answers appear sequentially, corresponding to VO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ON-SCREEN COPY:</strong> In-office penile modeling procedure should be performed _______ after the second injection of each treatment cycle:</td>
<td></td>
</tr>
<tr>
<td>a) Immediately</td>
<td></td>
</tr>
<tr>
<td>b) 15 to 60 minutes</td>
<td></td>
</tr>
<tr>
<td>c) 1 to 3 days</td>
<td></td>
</tr>
<tr>
<td>d) 5 to 7 days</td>
<td></td>
</tr>
<tr>
<td><strong>VO:</strong> How soon should the in-office penile modeling procedure be performed after the second injection of each treatment cycle:</td>
<td></td>
</tr>
<tr>
<td>a) Immediately</td>
<td></td>
</tr>
<tr>
<td>b) Fifteen to sixty minutes</td>
<td></td>
</tr>
<tr>
<td>c) One to three days</td>
<td></td>
</tr>
<tr>
<td>d) Five to seven days</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Frame 55A</th>
<th>VISUAL: The correct answer is highlighted.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ON-SCREEN COPY:</strong> In-office penile modeling procedure should be performed _______ after the second injection of each treatment cycle:</td>
<td></td>
</tr>
<tr>
<td>a) Immediately</td>
<td></td>
</tr>
<tr>
<td>b) 15 to 60 minutes</td>
<td></td>
</tr>
<tr>
<td>c) 1 to 3 days</td>
<td></td>
</tr>
<tr>
<td>d) 5 to 7 days</td>
<td></td>
</tr>
<tr>
<td><strong>VO:</strong> In-office penile modeling procedure should be performed <strong>one to three days</strong> after the second injection of each treatment cycle: [Ref: PI/p.9/§2.2/Penile Modeling for PD/¶1]</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Frame 56</th>
<th>VISUAL: Question appears on-screen and answers appear sequentially, corresponding to VO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ON-SCREEN COPY:</strong> When performing in-office penile modeling procedure, hold the pressure for 30 seconds and rest for 30 seconds for a total of:</td>
<td></td>
</tr>
<tr>
<td>a) 2 times</td>
<td></td>
</tr>
<tr>
<td>b) 3 times</td>
<td></td>
</tr>
<tr>
<td>c) 5 times</td>
<td></td>
</tr>
<tr>
<td>d) 10 times</td>
<td></td>
</tr>
<tr>
<td><strong>VO:</strong> When performing in-office penile modeling procedure, hold the pressure for thirty seconds and rest for thirty seconds for a total of:</td>
<td></td>
</tr>
<tr>
<td>a) Two times</td>
<td></td>
</tr>
<tr>
<td>b) Three times</td>
<td></td>
</tr>
<tr>
<td>c) Five times</td>
<td></td>
</tr>
<tr>
<td>d) Ten times</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Frame 56A</th>
<th>VISUAL: The correct answer is highlighted.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ON-SCREEN COPY:</strong> When performing in-office penile modeling procedure, hold the pressure for 30 seconds and rest for 30 seconds for a total of:</td>
<td></td>
</tr>
<tr>
<td>a) 2 times</td>
<td></td>
</tr>
<tr>
<td>b) 3 times</td>
<td></td>
</tr>
<tr>
<td>c) 5 times</td>
<td></td>
</tr>
<tr>
<td>d) 10 times</td>
<td></td>
</tr>
<tr>
<td><strong>VO:</strong> When performing in-office penile modeling procedure, hold the pressure for thirty seconds and rest for thirty seconds for a total of: <strong>three times.</strong> [Ref: PI/ p.9/§2.2/Penile Modeling Procedure/bullets 3 and 4]</td>
<td></td>
</tr>
</tbody>
</table>
### Frame 57
**VISUAL:** Question appears on-screen and answers appear sequentially, corresponding to VO

**ON-SCREEN COPY:** The patient should be instructed to perform at-home penile straightening activity on a spontaneous erection unrelated to sexual activity no more than once daily for 30 seconds. The patient should also be instructed to perform the stretching activity on the flaccid penis:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>a)</td>
<td>At no time</td>
</tr>
<tr>
<td>b)</td>
<td>Once daily for a total of 1 minute</td>
</tr>
<tr>
<td>c)</td>
<td>5 times daily for 30 seconds at a time</td>
</tr>
<tr>
<td>d)</td>
<td>3 times daily for 30 seconds at a time</td>
</tr>
</tbody>
</table>

**VO:**

The patient should be instructed to perform at-home penile *straightening* activity on a spontaneous *erection* unrelated to sexual activity no more than once daily for thirty seconds. How often should the patient perform the *stretching* activity on the *flaccid penis*:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>a)</td>
<td>At no time</td>
</tr>
<tr>
<td>b)</td>
<td>Once daily for a total of one minute</td>
</tr>
<tr>
<td>c)</td>
<td>Five times daily for thirty seconds at a time</td>
</tr>
<tr>
<td>d)</td>
<td>Three times daily for thirty seconds at a time</td>
</tr>
</tbody>
</table>

---

### Frame 57A
**VISUAL:** The correct answer is highlighted.

**ON-SCREEN COPY:** The patient should be instructed to perform at-home penile straightening activity on an erection unrelated to sexual activity once daily for 30 seconds. The patient should also be instructed to perform the stretching activity on the flaccid penis:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>a)</td>
<td>At no time</td>
</tr>
<tr>
<td>b)</td>
<td>Once daily for a total of 1 minute</td>
</tr>
<tr>
<td>c)</td>
<td>5 times daily for 30 seconds at a time</td>
</tr>
<tr>
<td>d)</td>
<td>3 times daily for 30 seconds at a time</td>
</tr>
</tbody>
</table>

**VO:**

Instruct the patient to perform the *stretching* activity on the *flaccid penis* **three times daily for thirty seconds at a time.**

[Ref: P1/p.10/$2.2$/Penile Modeling for PD/bullet 2]
### Frame 58

**VISUAL:** Title screen with XIAFLEX® logo and copy below.

**ON-SCREEN COPY:** XIAFLEX®
collagenase clostridium histolyticum
Instructions for Using the XIAFLEX® Patient Counseling Document

---

**VO:**
Instructions for using the XIAFLEX® Patient Counseling Document.

---

### Frame 59

**VISUAL:** Copy appears and scrolls as VO is heard

**ON-SCREEN COPY:** Prior to initiating treatment with XIAFLEX®, and as part of each treatment-related visit, discuss the following information included in the Patient Counseling Document with each patient:

- The risks of corporal rupture (penile fracture) and other serious penile injury
- Precautions related to the patient’s role in reducing the risks of these adverse outcomes
  - Advising patients not have sex between the first and second injections of a treatment cycle
  - Wait at least four weeks until after the second injection of each treatment cycle before resuming sexual activity
  - Do not use a vacuum erection device during treatment
  - Avoid activities that may cause straining of the abdominal muscles such as straining during bowel movements.
- Conditions under which patients should promptly contact their healthcare provider
- Clear instructions on at-home penile modeling activities
- Important information regarding the safe

**VO:**
Prior to initiating treatment with XIAFLEX®, and as part of each treatment-related visit, discuss the following information included in the Patient Counseling Tool with each patient:

- The risks of corporal rupture (penile fracture) and other serious penile injury
- Precautions related to the patient’s role in reducing the risk of adverse outcomes for example advising patients:
  - Not have sex between the first and second injections of a treatment cycle
  - Wait at least four weeks until after the second injection of each treatment cycle before resuming sexual activity
  - Not use a vacuum erection device during treatment
  - Avoid activities that may cause straining of the abdominal muscles such as straining during bowel movements.
- Conditions under which patients should promptly contact their healthcare provider
- Clear instructions on at-home penile modeling activities
### INSTRUCTIONS FOR USING THE XIAFLEX® PATIENT COUNSELING DOCUMENT

<table>
<thead>
<tr>
<th>use of XIAFLEX® in treating Peyronie’s disease</th>
<th>• Important information regarding the safe use of XIAFLEX® in treating Peyronie’s disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>The patient must be given a copy of the Patient Counseling Document to take home.</td>
<td>The patient must be given a copy of the Patient Counseling Document to take home.</td>
</tr>
<tr>
<td>In addition, provide a Medication Guide to each patient prior to each injection of XIAFLEX®.</td>
<td>In addition, provide a Medication Guide to each patient prior to each injection of XIAFLEX®.</td>
</tr>
</tbody>
</table>

---

**Frame 60**

**VISUAL:** Scrolling copy stops and fades to new copy

**ON-SCREEN COPY:** To obtain copies of the Patient Counseling Document:

- Visit www.XIAFLEXREMS.com
- Call 1-877-313-1235
- Or contact your XIAFLEX® sales representative

**VO:**

To obtain copies of the Patient Counseling Document:

- Visit www.XIAFLEXREMS.com
- Call 1-877-313-1235
- Or contact your XIAFLEX® sales representative
Thank you for taking the time to review the REMS training video for using XIAFLEX® in treating Peyronie’s disease. Here are some key points to remember.

### Storage and Handling

Prior to reconstitution, the vials of lyophilized powder of XIAFLEX® and sterile diluent should be stored in a refrigerator at two to eight degrees Celsius or thirty-six to forty-six degrees Fahrenheit. [Ref: PI/p.31/§16/¶1]

- Before preparing XIAFLEX®, allow vials to stand at room temperature for at least fifteen minutes and no longer than sixty minutes. [Ref: PI/p.7/§2.2/bullet a, lines 1-4]
- The reconstituted XIAFLEX® solution can be kept at room temperature of twenty to twenty-five degrees Celsius or sixty-eight to seventy-seven degrees Fahrenheit for up to one hour or refrigerated at two to eight degrees Celsius or thirty-six to forty-six degrees Fahrenheit for up to four hours prior to administration. [Ref: PI/p.8/§2.2/bullet f, lines 1-3]
**Frame 63**

**VISUAL:** Vial with reconstituted XIAFLEX®; clock illustrating 15-minute interval

**ON-SCREEN COPY:** Reconstituted XIAFLEX®
After refrigeration, let stand at room temperature for 15 minutes before use

**VO:**
If the reconstituted XIAFLEX® solution is refrigerated, allow this solution to return to room temperature for approximately fifteen minutes before use.

[Ref: PI/p.8/§2.2/bullet f, lines 3-5]

---

**Frame 64**

**VISUAL:** Gloved hands mark injection site with surgical marker.

**ON-SCREEN COPY:** XIAFLEX®
collagenase clostridium histolyticum

Identifying the Treatment Area
- Induce an erection
- Locate the point of maximum concavity
- Mark the area with a marker

**VO:**
Identifying the Treatment Area

After inducing an erection, locate the point of maximum concavity, or focal point in the bend of the penis, which is where the plaque and the curvature intersect.

[Ref: PI/p.8/§2.2/ID of Tx Area for PD, bullet a, sub-bullets 1-2]
### Frame 65

**VISUAL:** Two gloved hands inject penis with syringe; copy bullets appear, corresponding with VO

**ON-SCREEN COPY:** Injection Procedure
- Withdraw 0.25 mL of reconstituted XIAFLEX® solution
- Penis should be flaccid
- Place needle tip on the side of the plaque in alignment with the point of maximal concavity
- Insert and advance the needle transversely
- Confirm proper positioning by noting resistance in syringe plunger
- Deposit full dose within the plaque

**VO:**

**INJECTION PROCEDURE**
Withdraw 0.25 mL of reconstituted XIAFLEX® solution. [Ref: PI/p. 8/§2.2/Inj Procedure for PD/bullet d]

The penis should be in a flaccid state before injecting XIAFLEX®. Place the needle tip on the side of the target plaque in alignment with the point of maximal concavity. Orient the needle so that it enters the plaque from the side, NOT downward or perpendicularly toward the body of the corpora cavernosum. [Ref: PI/p. 8/§2.2/Inj Procedure for PD/bullet e]

Insert and advance the needle transversely through the width of the plaque, toward the opposite side of the plaque without passing completely through it. Proper needle position is confirmed by carefully noting resistance to minimal depression of the syringe plunger. [Ref: PI/p. 9/§2.2/Inj Procedure for PD/bullet f]

Withdraw the needle slowly, so as to deposit the full dose along the needle track within the plaque. The goal is always to deposit the full dose entirely within the plaque. [Ref: PI/p. 9/§2.2/Inj Procedure for PD/bullet g]

### Frame 66

**VISUAL:** Gloved hands bending penis opposite to penile curvature, with stretching to the point of moderate resistance.

**ON-SCREEN COPY:**

**VO:**

**PENILE MODELING (IN-OFFICE AND AT-HOME)**
In-office penile modeling procedure should be performed one to three days after the second injection of each treatment cycle. [Ref: PI/p. 9/§2.2/Penile Modeling Procedure/¶ 1]

Using the target plaque as a fulcrum point, use both hands to apply firm, steady pressure to elongate and stretch the plaque. The goal is to gradually create bending opposite to the patient’s penile curvature, with stretching to the point of moderate resistance. Hold pressure for thirty seconds and then release. [Ref: PI/p. 9/§2.2/Penile Modeling Procedure/bullet 3]
<table>
<thead>
<tr>
<th>SUMMARY</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Create a reverse bend</td>
</tr>
<tr>
<td>- Stretch to point of moderate resistance</td>
</tr>
<tr>
<td>- Hold for 30 seconds</td>
</tr>
</tbody>
</table>

**IN-OFFICE PENILE MODELING**

<p>| |</p>
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>After a thirty-second rest period, repeat the penile modeling technique for a total of three times at thirty seconds each.</td>
</tr>
<tr>
<td>[Ref: PI/p.9/§2.2/Penile Modeling Procedure/bullet 4]</td>
</tr>
</tbody>
</table>

**Frame 67**

**At-home penile modeling activities:**

- **Stretching**
  - On flaccid penis: Stretch 3 times daily for 30 seconds at a time
  - On erect penis: Gently straighten and hold for 30 seconds once per day

**Visual:** Illustrations of stretching and straightening technique for at-home penile modeling

**ON-SCREEN COPY:** At-home penile modeling activity:

- On flaccid penis: Stretch 3 times daily for 30 seconds at a time
- On erect penis: Gently straighten and hold for 30 seconds once per day

**At-home penile modeling activities involve a gentle stretching and straightening of the penis.**  
[Ref: PI/p.9/§2.2/Penile Modeling for PD/¶2]

The stretching activity should be performed three times daily and when the penis is not erect. Stretching should last for thirty seconds.  
[Ref: PI/p.10/§2.2/Penile Modeling for PD/bullet 2]

The straightening activity is performed for thirty seconds, no more than once per day on a spontaneous erection unrelated to sexual activity.  
[Ref: PI/p.10/§2.2/Penile Modeling for PD/bullet 1]

Remember, prior to initiating treatment and as part of each treatment-related visit, use the XIAFLEX® Patient Counseling Tool to discuss important information with each patient.
If you have product-related questions or to report adverse events, please contact the XIAFLEX® Medical Information Call Center at 1-800-462-3636.
Healthcare Provider Enrollment Form for Peyronie’s Disease

To submit this form, please complete all required fields as indicated with an asterisk (*), fax completed form to XIAFLEX® at 1-877-313-1236 or mail to XIAFLEX® REMS Program, PO Box 2957, Phoenix, AZ 85062-2957. You will receive confirmation of certification within 2 business days after your form is received by Endo Pharmaceuticals. For questions regarding the XIAFLEX® REMS Program for Peyronie’s disease, call 1-877-313-1235.

Healthcare Provider responsibilities for the use of XIAFLEX® in the treatment of Peyronie’s disease:
I understand that XIAFLEX® is only available for the treatment of Peyronie’s disease through the XIAFLEX® REMS Program.

I confirm that to be specially certified I have met all of the following requirements:
• I am a healthcare provider knowledgeable in the management of male urological diseases.
• I have read the Prescribing Information for XIAFLEX®, including the risks associated with the use of XIAFLEX® and how to properly administer XIAFLEX® for Peyronie’s disease.
• I have completed the XIAFLEX® REMS training video and/or training guide for the treatment of Peyronie’s disease.
• Prior to initiating treatment, and as part of each treatment-related visit, I agree to review with and provide a copy of the Patient Counseling Tool, “What You Need to Know About XIAFLEX® Treatment for Peyronie’s Disease: A Patient Guide,” to each patient to inform patients about the risks associated with the use of XIAFLEX® and the need to follow important post-injection instructions.
• I acknowledge that my practice setting must be a certified healthcare setting, or that I will use a certified pharmacy, enrolled in the XIAFLEX® REMS Program.
• I agree that I will make available to Endo Pharmaceuticals, and/or a designated third party or the FDA, documentation to verify understanding of, and adherence to, the XIAFLEX® REMS requirements.

I understand that this enrollment and certification only applies to me, and does not apply to any Healthcare Setting that employs me, or in which I may have an interest. Failure to enroll and become certified in the XIAFLEX® REMS Program for Peyronie’s disease as a Healthcare Provider will result in my inability to receive shipments of XIAFLEX®.

Healthcare Provider Name*  Signature*  Date*

HEALTHCARE PROVIDER INFORMATION
First Name*  MI  Last*  Suffix  Degree*  Phone Type
Fax*  Phone*  Email*  Preferred method of contact* is:
Provide as appropriate:
NPI #*  ME #  License # and State
Specialty:*  General Surgeon  Plastic Surgeon  Urologist  Other (specify)

PRACTICE INFORMATION
Practice Name*
Address*
City*  State*  ZIP*
Primary Treatment Setting:*  Inpatient  Outpatient/Clinic (not affiliated with hospital)  Outpatient/Clinic (affiliated with hospital)
To enroll, the pharmacy or healthcare setting must designate an Authorized Representative to coordinate the setting’s activities and assure compliance with the XIAFLEX® REMS Program for Peyronie’s disease.

To submit this form, please complete all required fields as indicated with an asterisk (*), fax completed form to XIAFLEX® at 1-877-313-1236 or mail to XIAFLEX® REMS Program, PO Box 2957, Phoenix, AZ 85062-2957. You will receive an enrollment confirmation within 2 business days after your form is received by Endo Pharmaceuticals. For questions regarding the XIAFLEX® REMS Program for Peyronie’s disease, call 1-877-313-1235.

AUTHORIZED REPRESENTATIVE RESPONSIBILITIES
I understand that XIAFLEX® is only available through the XIAFLEX® REMS Program for Peyronie’s disease. I am the Authorized Representative designated by my pharmacy or healthcare setting to coordinate the activities of the XIAFLEX® REMS. I agree to comply with the following program requirements:

- Ensure that the staff responsible for dispensing and administering XIAFLEX® at this healthcare setting is aware of my responsibilities as the Authorized Representative.
- Prior to dispensing XIAFLEX®, confirm that the Healthcare Provider treating Peyronie’s disease is specially certified in the XIAFLEX® REMS Program for Peyronie’s disease.
- Maintain a current list of Healthcare Providers (HCP) affiliated with my healthcare setting who are specially certified. The current affiliated Healthcare Providers of this healthcare setting include the individuals listed below. I will maintain this list by adding or removing affiliated Healthcare Providers as appropriate.
- Agree not to loan, sell or transfer XIAFLEX® to another pharmacy, healthcare setting, prescriber, institution or distributor.
- Make available to Endo Pharmaceuticals, and/or a designated third party or the FDA, documentation to verify understanding of, and adherence to, the requirements of the XIAFLEX® REMS.

I understand that this enrollment only applies to me as the designated Authorized Representative of this pharmacy or healthcare setting. I will complete a separate enrollment form for each pharmacy or healthcare setting (unique ship-to site address) for which my designation and responsibilities extend. Failure to enroll a pharmacy or healthcare setting in the XIAFLEX® REMS Program for Peyronie’s disease will result in the inability to receive shipments of XIAFLEX®.

HCP First and Last Name*  HCP Enrollment ID #*

For additional Affiliated Healthcare Setting Providers, please continue on page 2.

Authorized Representative* (Please Print)

Signature*  Date*

© 2018 Endo Pharmaceuticals Inc.  July 2018
To enroll, the pharmacy or healthcare setting must designate an Authorized Representative to coordinate the setting’s activities and assure compliance with the XIAFLEX® REMS Program for Peyronie’s disease.

**INSTRUCTIONS:** Fax completed form to XIAFLEX® at 1-877-313-1236 or mail to XIAFLEX® REMS Program, PO Box 2957, Phoenix, AZ 85062-2957. You will receive an enrollment confirmation within 2 business days after your form is received by Endo Pharmaceuticals. For questions regarding the XIAFLEX® REMS Program for Peyronie’s disease, call 1-877-313-1235.

### AFFILIATED HEALTHCARE SETTING HEALTHCARE PROVIDERS

<table>
<thead>
<tr>
<th>HCP First and Last Name</th>
<th>HCP Enrollment ID #</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
What You Need to Know About XIAFLEX® Treatment for Peyronie’s Disease: A Patient Guide

Patients: Keep this guide for important safety information and instructions for your at-home activities.

Healthcare Providers: Review this guide with your patients and give them a copy.

XIAFLEX® is a prescription medicine used to treat adult men with Peyronie’s disease with an abnormally curved penis and a plaque that can be felt.

What are the serious risks of XIAFLEX® treatment?

XIAFLEX® can cause serious side effects including:

Penile fracture (corporal rupture) or other serious injury to the penis.
Receiving an injection of XIAFLEX® may cause damage to the tubes in your penis called the corpora. After treatment with XIAFLEX®, one of these tubes may break during an erection. This is called a corporal rupture or penile fracture. This could require surgery to fix the damaged area. Damage to your penis might not get better after corporal rupture.

After treatment, blood vessels in your penis may also break, causing blood to collect under the skin (hematoma). This could require a procedure to drain the blood from under the skin.

Do not have sex or any other sexual activity between the first and second injections of a treatment cycle with XIAFLEX®.
Do not have sex or any other sexual activity for at least 4 weeks after the second injection of a treatment cycle with XIAFLEX® and after any pain and swelling have gone away, or until given permission by your healthcare provider.

When should I call my healthcare provider?

Call your healthcare provider right away if you have any of the following symptoms of penile fracture or other serious injury to the penis:

• Severe purple bruising and swelling of your penis
• Severe pain in your penis
• A popping sound or sensation in an erect penis
• Sudden loss of the ability to maintain an erection
• Difficulty urinating or blood in the urine

You may report side effects to the FDA at 1-800-FDA-1088 or to the XIAFLEX® Medical Information Call Center at 1-800-462-3636.
How can I lower the risks associated with XIAFLEX®?

Before treatment:

• Tell your healthcare provider if you have ever had an allergic reaction to XIAFLEX®.
• Tell your healthcare provider about all the medications you take, especially blood thinner medicines such as aspirin, clopidogrel bisulfate (PLAVIX), prasugrel hydrochloride (EFFIENT) or warfarin sodium (COUMADIN). If you are told to stop taking a blood thinner before your XIAFLEX® injection, your healthcare provider should tell you when to restart the blood thinner.
• Tell your healthcare provider if you have any bleeding problems or if you have other medical conditions.

After treatment:

• Within 24 hours after treatment, your penis may appear bruised and/or swollen and you may have mild-to-moderate penile pain. Ask your healthcare provider if over-the-counter medications are appropriate.
• Do not have sex between the first and second injections of a treatment cycle with XIAFLEX®.
• Do not have sex or have any other sexual activity for at least 4 weeks following the second injection of a treatment cycle with XIAFLEX® and after any pain and swelling have gone away, or until given permission by your healthcare provider.
• Do the gentle stretching and straightening of your penis at home as shown below.
• Do not use a vacuum erection device during your treatment with XIAFLEX®
• Avoid situations that may cause you to strain your stomach (abdominal) muscles, such as straining during bowel movements
• Return to your healthcare provider’s office when directed for further injection(s) and/or penile modeling procedures.

What do I need to do at home?

For the 6 weeks after each treatment cycle, you will need to perform the following gentle penile stretching and straightening activities. Your doctor will tell you exactly when to start and how long to continue.

1) Penile Stretches (when penis is not erect)

• Grasp the tip of your penis with the fingers of one hand and hold the base of your penis with the fingers of your other hand (see diagram).
• Gently pull your penis away from your body to its full length.
• Hold the stretch for 30 seconds.
• Let go and allow your penis to return to its normal, unstretched length.
• Do this stretching three times each day, only when the penis is not erect.

2) Penile Straightening (when penis is erect)

• If you have a spontaneous erection, not related to sexual activity, attempt to straighten your penis by gently bending the shaft in the opposite direction of the curve, but not so forcefully so as to produce significant pain or discomfort.
• Hold the penis in this more straightened position for 30 seconds, then let go.
• Do this straightening activity only one time each day. If you do not have a spontaneous erection, do not attempt the penile straightening activity.

© 2018 Endo Pharmaceuticals Inc. July 2018
What is XIAFLEX

XIAFLEX is approved for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. XIAFLEX should be administered by a healthcare provider experienced in the treatment of male urological diseases, who has completed required training for use of XIAFLEX in the treatment of Peyronie’s disease.

What is the XIAFLEX REMS

A REMS (Risk Evaluation and Mitigation Strategy) is a strategy to manage known or potential serious risks associated with a drug and is required by the Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks. Endo Pharmaceuticals has worked with the FDA to develop the XIAFLEX REMS Program.

The XIAFLEX REMS requires a review of educational materials, training, and certification.

XIAFLEX is available for the treatment of Peyronie’s disease only through the XIAFLEX REMS Program. The XIAFLEX REMS Program requirements include:

- **Training** for healthcare providers on the risks of corporal rupture and other serious injuries to the penis, and how to properly administer XIAFLEX.
- **Certification** in the XIAFLEX REMS Program by completing training and enrollment in the program.
- **Patient Counseling** about the risks of corporal rupture and other serious injuries to the penis and the importance of patient adherence to post-injection instructions. Healthcare Providers must give patients the Patient Counseling Tool, "What You Need to Know About XIAFLEX Treatment for Peyronie’s Disease: A Patient Guide", after each XIAFLEX injection.
- **Restricted Distribution** through specially certified healthcare settings (e.g., pharmacies, practitioners, hospitals or outpatient settings).

**Healthcare Provider Certification**

To become certified in the XIAFLEX REMS Program, healthcare providers must read the prescribing information, take the training video or guide and complete the Enrollment Form.

**Pharmacy/Healthcare Setting Certification**

To become certified in the XIAFLEX REMS Program, pharmacies and healthcare settings must complete the Pharmacy/Healthcare Setting Enrollment Form.

For more information about the XIAFLEX REMS Program, call 1-877-313-1235.

If you have product-related questions or to report adverse events, please contact the XIAFLEX Medical Information Call Center at 1-800-482-3636. Adverse events may also be reported to the FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

---

**Materials for Healthcare Providers**

- Healthcare Provider Enrollment Form for Peyronie’s Disease
- Training Guide for the Administration of XIAFLEX for Peyronie’s Disease
- Training Video for the Administration of XIAFLEX for Peyronie’s Disease
- What You Need to Know About XIAFLEX Treatment for Peyronie’s Disease: A Patient Guide (a patient counseling tool)
- Prescribing Information
- Medication Guide

**Materials for Healthcare Facilities**

- Healthcare Facility Enrollment Form for Peyronie’s Disease

**Materials for Patients**

- What You Need to Know about XIAFLEX Treatment for Peyronie’s Disease: A Patient Guide
- Medication Guide

**Resources**

- Certified Healthcare Setting and Healthcare Provider Lookup
XIAFLEX®
collagenase clostridium histolyticum

XIAFLEX REMS Program Certification Lookup

To use the Program Certification Lookup, please start by choosing a tab: either Prescribing Healthcare Provider or Healthcare Setting. If searching for a Prescribing Healthcare Provider, please enter the Zip Code or Certification ID or NPI Number or Last Name and State and press the Search button. If searching for a Healthcare Setting, please enter the Certification ID or the Zip Code or City and State and press the Search button. Search results include contact information and certified participants/locations in the XIAFLEX REMS Program.

<table>
<thead>
<tr>
<th>Prescribing Healthcare Provider</th>
<th>Healthcare Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zip Code</td>
<td>Certification ID</td>
</tr>
<tr>
<td>——</td>
<td>——</td>
</tr>
</tbody>
</table>

Search

Show 10 entries

Certification ID | Name | Address | City | State | Zip | Phone
--- | --- | --- | --- | --- | --- | ---
 Item

Privacy Policy | Terms and Conditions

© 2018 Endo Pharmaceuticals Inc. All rights reserved. Malvern, PA 19355
XIAFLEX®
collagenase clostridium histolyticum

XIAFLEX REMS Program Certification Lookup

To use the Program Certification Lookup, please start by choosing a tab, either Prescribing Healthcare Provider or Healthcare Setting. If searching for a Prescribing Healthcare Provider, please enter the Zip Code or Certification ID or NPI Number or Last Name and State and press the Search button. If searching for a Healthcare Setting, please enter the Certification ID or the Zip Code or City and State and press the Search button. Search results include contact information and certified participants/locations in the XIAFLEX REMS Program.

<table>
<thead>
<tr>
<th>Prescribing Healthcare Provider</th>
<th>Healthcare Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zip Code</td>
<td>Certification ID</td>
</tr>
<tr>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Certification ID</th>
<th>Name</th>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>Zip</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>3112345</td>
<td>JOHN MULYE</td>
<td>900 East Valley street 123</td>
<td>Baltimore</td>
<td>Maryland</td>
<td>03909</td>
<td>480-505-7800</td>
</tr>
</tbody>
</table>

1 - 1 of 1 item

Show 10 entries
XIAFLEX REMS Program Certification Lookup

To use the Program Certification Lookup, please start by choosing a tab: either Prescribing Healthcare Provider or Healthcare Setting. If searching for a Prescribing Healthcare Provider, please enter the Zip Code or Certification ID or NPI Number or Last Name and State and press the Search button. If searching for a Healthcare Setting, please enter the Certification ID or the Zip Code or City and State and press the Search button. Search results include contact information and certified participants/locations in the XIAFLEX REMS Program.

<table>
<thead>
<tr>
<th>Prescribing Healthcare Provider</th>
<th>Healthcare Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certification ID</td>
<td>Zip Code</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Search

<table>
<thead>
<tr>
<th>Certification ID</th>
<th>Name</th>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>Zip</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**XIAFLEX REMS Program Certification Lookup**

To use the Program Certification Lookup, please start by choosing a tab, either Prescribing Healthcare Provider or Healthcare Setting. If searching for a Prescribing Healthcare Provider, please enter the Zip Code or Certification ID or NPI Number or Last Name and State and press the **Search** button. If searching for a Healthcare Setting, please enter the Certification ID or the Zip Code or City and State and press the **Search** button. Search results include contact information and certified participants/locations in the XIAFLEX REMS Program.

<table>
<thead>
<tr>
<th>Prescribing Healthcare Provider</th>
<th>Healthcare Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certification ID</td>
<td>Zip Code</td>
</tr>
<tr>
<td>__________________</td>
<td>_________</td>
</tr>
<tr>
<td>-or-</td>
<td>-or-</td>
</tr>
</tbody>
</table>

**Table:**

<table>
<thead>
<tr>
<th>Certification ID</th>
<th>Name</th>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>Zip</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>2112345</td>
<td>ABC Pharmacy</td>
<td>903 East Utility street 123</td>
<td>Baltimore</td>
<td>Maryland</td>
<td>03909</td>
<td>410-123-4567</td>
</tr>
</tbody>
</table>

*1 of 1 item*